These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cannabinoids, interoception, and anxiety. Andrade AK; Renda B; Murray JE Pharmacol Biochem Behav; 2019 May; 180():60-73. PubMed ID: 30922834 [TBL] [Abstract][Full Text] [Related]
4. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Rubino T; Guidali C; Vigano D; Realini N; Valenti M; Massi P; Parolaro D Neuropharmacology; 2008 Jan; 54(1):151-60. PubMed ID: 17692344 [TBL] [Abstract][Full Text] [Related]
5. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Rey AA; Purrio M; Viveros MP; Lutz B Neuropsychopharmacology; 2012 Nov; 37(12):2624-34. PubMed ID: 22850737 [TBL] [Abstract][Full Text] [Related]
6. Receptor mechanisms underlying the CNS effects of cannabinoids: CB Hempel B; Xi ZX Adv Pharmacol; 2022; 93():275-333. PubMed ID: 35341569 [TBL] [Abstract][Full Text] [Related]
7. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047 [TBL] [Abstract][Full Text] [Related]
8. Effects of nicotine and a cannabinoid receptor agonist on negative contrast: distinction between anxiety and disappointment? Genn RF; Tucci S; Parikh S; File SE Psychopharmacology (Berl); 2004 Dec; 177(1-2):93-9. PubMed ID: 15205871 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
11. Evaluating Potential Anxiolytic Effects of Minor Cannabinoids and Terpenes After Acute and Chronic Oral Administration in Rats. Jenkins BW; Moore CF; Covey D; McDonald JD; Lefever TW; Bonn-Miller MO; Weerts EM Cannabis Cannabinoid Res; 2023 Sep; 8(S1):S11-S24. PubMed ID: 37721993 [No Abstract] [Full Text] [Related]
12. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon LR J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255 [TBL] [Abstract][Full Text] [Related]
15. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Lile JA; Kelly TH; Hays LR Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600 [TBL] [Abstract][Full Text] [Related]